Literature DB >> 17471824

Cytokine-release syndrome: overview and nursing implications.

Sheila Breslin1.   

Abstract

Cytokine-release syndrome is a symptom complex associated with the use of many monoclonal antibodies. Commonly referred to as an infusion reaction, it results from the release of cytokines from cells targeted by the antibody as well as immune effector cells recruited to the area. When cytokines are released into the circulation, systemic symptoms such as fever, nausea, chills, hypotension, tachycardia, asthenia, headache, rash, scratchy throat, and dyspnea can result. In most patients, the symptoms are mild to moderate in severity and are managed easily. However, some patients may experience severe, life-threatening reactions that result from massive release of cytokines. Severe reactions occur more commonly during the first infusion in patients with hematologic malignancies who have not received prior chemotherapy; severe reactions are marked by their rapid onset and the acuity of associated symptoms. Massive cytokine release is an oncologic emergency, and special precautions must be taken to prevent life-threatening complications. This article will present an overview of the etiology and management of cytokine-release syndrome in patients receiving monoclonal antibodies to better prepare oncology nurses to safely care for such patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17471824     DOI: 10.1188/07.CJON.S1.37-42

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  20 in total

1.  Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies.

Authors:  Miriam López-Gómez; César Gómez-Raposo; María Sereno; Francisco Zambrana; Enrique Casado
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

Review 2.  Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.

Authors:  Nicholas R Harrison; Fabrice J F Laroche; Alejandro Gutierrez; Hui Feng
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 3.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 4.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors:  Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

5.  Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Acc Chem Res       Date:  2015-05-26       Impact factor: 22.384

6.  Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment.

Authors:  Carissa Laudati; Caroline Clark; Andrea Knezevic; Zhigang Zhang; Margaret Barton-Burke
Journal:  Clin J Oncol Nurs       Date:  2018-08-01       Impact factor: 1.027

7.  Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers.

Authors:  Emi Goto; Toshifumi Yamaguchi; Nobuhiro Hattori; Masahiro Goto; Masami Nishihara; Kazuhisa Uchiyama; Yoshiyuki Rikitake
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 8.  Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis.

Authors:  Sadia Nosher; Sehrish Fuad; Nupur Mishra; Zaid A Alrashid; Bindu Rathod; Devyani Mohan; Deepak M Basavanagowda; Arveen Kaur; Stacey E Heindl
Journal:  Cureus       Date:  2021-02-09

9.  Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.

Authors:  María Rosario Blasco; Antonio Ramos; Celia García Malo; Antonio García-Merino
Journal:  J Neurol       Date:  2016-11-25       Impact factor: 6.682

Review 10.  Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety.

Authors:  Irena Vlatkovic
Journal:  Biomedicines       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.